17,794 Shares in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Bought by Marshall Wace LLP

Marshall Wace LLP acquired a new stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 17,794 shares of the company’s stock, valued at approximately $117,000. Marshall Wace LLP owned 0.05% of Lexeo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the business. Jane Street Group LLC increased its holdings in shares of Lexeo Therapeutics by 33.3% in the 3rd quarter. Jane Street Group LLC now owns 35,677 shares of the company’s stock worth $323,000 after buying an additional 8,918 shares during the last quarter. Barclays PLC raised its position in Lexeo Therapeutics by 162.2% during the third quarter. Barclays PLC now owns 50,210 shares of the company’s stock valued at $454,000 after purchasing an additional 31,057 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Lexeo Therapeutics by 135.6% during the third quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after purchasing an additional 5,915 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Lexeo Therapeutics during the 4th quarter valued at about $72,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Lexeo Therapeutics during the fourth quarter valued at approximately $46,000. 60.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Royal Bank of Canada reduced their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 25th. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th. Leerink Partners dropped their price objective on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Monday, March 24th. Finally, Chardan Capital decreased their target price on shares of Lexeo Therapeutics from $25.00 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, April 8th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $22.20.

Lexeo Therapeutics Stock Performance

Lexeo Therapeutics stock opened at $3.25 on Wednesday. Lexeo Therapeutics, Inc. has a fifty-two week low of $1.45 and a fifty-two week high of $19.50. The stock’s 50 day simple moving average is $3.04 and its two-hundred day simple moving average is $5.32. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. The stock has a market cap of $107.89 million, a price-to-earnings ratio of -1.03 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.09. As a group, analysts expect that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current fiscal year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.